LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver ...
Chronic hepatitis B is a viral disease that affects the liver and greatly increases the risks of liver cirrhosis and ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Read more about how a dive in HBV rates in infants in the USA has undone years of steady increase in vaccination uptake.
Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...
Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions ...
GSK’s bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B: London, UK Friday, February 27, 2026, 09:00 Hrs [IST] ...
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and ...
EMBRACE reported 12-month suppression rates of 94% (IV N6LS+CAB LA), 82% (SC), and 88% (oral SOC), with no virologic failures ...
INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults ...
Studies show that up to 50% of patients may experience recurrence within two to three years after curative surgery. By five ...
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results